Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Abpro, AstraZeneca deal

    The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 (ANG2; ANGPT2) and VEGF for multiple undisclosed indications. Abpro will use …

    Published on 12/5/2016
  • Allergan, Chase deal

    Allergan acquired Chase for $125 million up front, plus undisclosed milestones tied to the company's CPC-201 to treat Alzheimer's disease. Allergan said it plans to begin a Phase III trial of CPC-201 next year. Chase …

    Published on 12/5/2016
  • Bicycle, AstraZeneca deal

    Bicycle and AstraZeneca partnered to identify and develop bicyclic peptides to treat respiratory, cardiovascular and metabolic diseases. Bicyclic peptides are small molecules designed to show affinity and target …

    Published on 12/5/2016
  • Boehringer, China Southeast University deal

    Boehringer said it will collaborate with the university's Institute of Life Sciences to develop regenerative therapies to treat hearing loss. The collaboration is part of Boehringer's Research Beyond Borders (RBB) …

    Published on 12/5/2016
  • Cellect, Hadassah deal

    Hadassah's Hadasit Ltd. technology transfer arm partnered with Cellect to conduct preclinical studies of Cellects ApoGraft to treat graft-versus-host disease (GvHD). Hadassah will conduct the studies. ApoGraft consists …

    Published on 12/5/2016
  • Chiesi, Atopix deal

    Chiesi will acquire Atopix in a deal that could exceed 75 million ($80 million), including undisclosed milestones. Atopixs OC459, a prostaglandin D2 (PGD2) receptor subtype DP2 (PTGDR2; CRTH2; GPR44; DP2; CD294) …

    Published on 12/5/2016
  • Chugai, Menarini deal

    Chugai granted Menarini exclusive, worldwide rights to develop and commercialize cancer candidate PA799. Chugai will receive an undisclosed upfront payment and is eligible for undisclosed milestones and royalties. PA799…

    Published on 12/5/2016
  • Evotec, Merck KGaA deal

    The companies will combine Mercks CRISPR-associated protein 9 (Cas9) gene editing technology and short hairpin RNA (shRNA) library with Evotecs phenotypic screening in induced pluripotent stem cells and in vivo disease …

    Published on 12/5/2016
  • Genetic Analysis, Bio-Rad deal

    Microbiome company Genetic Analysis granted Bio-Rad rights to commercialize Genetic Analysis' GA-map technology in undisclosed regions to detect gut dysbiosis. Genetic Analysis will receive an undisclosed equity …

    Published on 12/5/2016
  • Halozyme, AbbVie deal

    Halozyme said AbbVie discontinued the partners first program under a 2015 deal to develop AbbVie compounds using Halozymes Enhanze drug delivery platform. The platform uses recombinant human enzyme sperm adhesion …

    Published on 12/5/2016
  • Heptares, G7 deal

    Sosei's Heptares Therapeutics Ltd. subsidiary will acquire drug discovery and development company G7 for CHF12 million ($11.9 million) in cash. The acquisition combines Heptares' GPCR targeting technology StaR with G7's…

    Published on 12/5/2016
  • Horizon Discovery deal

    Horizon will provide its HDx Reference Standards to three undisclosed Chinese diagnostic kit developers for use in the firms next-generation sequencing (NGS) assay development. The HDx standards will serve as quality …

    Published on 12/5/2016
  • IBM, Pfizer deal

    IBM and Pfizer partnered to accelerate Pfizer's immuno-oncology research. IBM will provide it's cloud based Watson for Discovery platform which will analyze proprietary data from the pharma as well as data from public …

    Published on 12/5/2016
  • Idera, Vivelix deal

    Idera granted Vivelix exclusive, worldwide rights to develop and commercialize IMO-9200 to treat non-malignant gastrointestinal disorders. Idera will receive $15 million up front and is eligible for up to $65 million in…

    Published on 12/5/2016
  • Kamada, Yissum deal

    Kamada and the university's Yissum Research Development Co. partnered to develop a eukaryotic expression system for recombinant human alpha-1 antitrypsin (AAT). Kamada said it will have the rights to the system and …

    Published on 12/5/2016
  • Lilly, IntelGenx deal

    Eli Lilly granted IntelGenx rights to U.S. Patent No. 6,943,166, which covers dosing of Lillys tadalafil. IntelGenx says the deal will allow it to commercialize its Tadalafil ED Versafilm in the U.S. before the …

    Published on 12/5/2016
  • Navidea, Cardinal Health deal

    Navidea will sell its Lymphoseek tilmanocept imaging agent to Cardinal Health for oncology indications for $80 million up front and up to $230 million in annual earn-out and sales milestone payments. Prior to the deal, …

    Published on 12/5/2016
  • Novartis, Selexys deal

    Novartis exercised a 2012 option to acquire Selexys for $240 million. Under a 2012 deal, the pharma held the option to acquire Selexys following data from the Phase II SUSTAIN trial of lead compound SelG1 -- a humanized…

    Published on 12/5/2016
  • OpGen, Merck deal

    The companies partnered to develop diagnostics to detect antimicrobial resistance. Merck will provide OpGen access to its bacterial pathogens archive, and OpGen will perform genomic analysis, drug resistance testing and…

    Published on 12/5/2016
  • Portage spins out EyGen

    Portage spun out EyGen Ltd. (Toronto, Ontario), which will focus on developing preclinical opthalmologic and inflammatory compounds through proof of concept. The newco's lead compound is Portages PPL-003, a cell …

    Published on 12/5/2016
  • Proteros, Merck deal

    Proteros and Merck partnered to develop small molecules against an epigenetic target to treat cancer. Proteros will receive an undisclosed upfront payment and R&D funding and is eligible for up to $167 million in …

    Published on 12/5/2016
  • Tokushima University, Shionogi deal

    The university granted Shionogi exclusive, worldwide rights to develop A2NTX, a low molecular weight botulinum neurotoxin type A2 that is being developed to treat post-stroke spasticity of the upper and lower limbs. The…

    Published on 12/5/2016
  • Triphase, Celgene deal

    Triphase said Celgene exercised its option to acquire proteasome inhibitor marizomib (NPI-0052). Triphase will receive an undisclosed upfront payment and is eligible for milestones. Celgene will be responsible for …

    Published on 12/5/2016
  • Vectura, Hikma deal

    Vectura Group plc (LSE:VEC), Chippenham, U.K.Hikma Pharmaceuticals plc (LSE:HIK), London, U.K.Business: Pulmonary, Inflammation, Drug deliveryVectura granted Hikma U.S. rights to develop and commercialize VR730, a …

    Published on 12/5/2016
  • Acticor, Mediolanum deal

    Acticor and Mediolanum partnered to develop Acticors acute ischemic stroke candidate ACT-017. Mediolanum will co-own the results of the collaboration and acquire marketing rights in two undisclosed European countries. …

    Published on 11/21/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993